Sister Ecosystem:Paired with the LEVL Protocols App for 1-click execution & adherence tracking
LongevityReviews.org
Evidence Consensus Engine
Back to All Modalities
Raw MarkdownTrack in LEVL
Executive Evidence Consensusgold • 97/100

Apolipoprotein B-100 (ApoB) is the single most accurate, direct measure of atherogenic particle concentration, accounting for all circulating LDL, VLDL, IDL, and Lp(a) particles. Landmark consensus established by the Sniderman 2019 meta-analysis (233,455 subjects) and Marston 2022 FOURIER/IMPROVE-IT trials confirms that cardiovascular risk tracks strictly with ApoB particle number rather than LDL cholesterol mass, particularly in discordance scenarios (metabolic syndrome, insulin resistance, hypertriglyceridemia). As a diagnostic surveillance modality, optimal longevity targets are <60 mg/dL (<40 mg/dL for documented CAD).

Knowledge Graph:Vector: HeartIntercellular Signaling
Head-to-Head CompareAudit in Stack
Diagnostics & TrackingHeartGold Tier95+1stin Diagnostics of 702ndin Calmness of 33Top 5in Intercellular Signaling of 74High Confidence (Human RCTs)📈 Scientific Consensus: Rising

ApoB & Advanced Lipid Panel

Apolipoprotein B-100 (ApoB) is the single most accurate, direct measure of atherogenic particle concentration, accounting for all circulating LDL, VLDL, IDL, and Lp(a) particles. Landmark consensus established by the Sniderman 2019 meta-analysis (233,455 subjects) and Marston 2022 FOURIER/IMPROVE-IT trials confirms that cardiovascular risk tracks strictly with ApoB particle number rather than LDL cholesterol mass, particularly in discordance scenarios (metabolic syndrome, insulin resistance, hypertriglyceridemia). As a diagnostic surveillance modality, optimal longevity targets are <60 mg/dL (<40 mg/dL for documented CAD).

97/100
Elite Anchor
1-Click Track in LEVL App
1. Current Scientific Consensus

Apolipoprotein B-100 (ApoB) is the single most accurate, direct measure of atherogenic particle concentration, accounting for all circulating LDL, VLDL, IDL, and Lp(a) particles. Landmark consensus established by the Sniderman 2019 meta-analysis (233,455 subjects) and Marston 2022 FOURIER/IMPROVE-IT trials confirms that cardiovascular risk tracks strictly with ApoB particle number rather than LDL cholesterol mass, particularly in discordance scenarios (metabolic syndrome, insulin resistance, hypertriglyceridemia). As a diagnostic surveillance modality, optimal longevity targets are <60 mg/dL (<40 mg/dL for documented CAD).

2. Major Unanswered Scientific Uncertainty

Paucity of universal clinical guideline adoption due to legacy reliance on standard Friedewald LDL-C calculations and non-standardized commercial assay pricing.

Strongest Supporting TrialPMID:31215987

Apolipoprotein B Particles and Cardiovascular Events: A Systematic Review and Meta-analysis

Systematic Review and Meta-Analysis • Sample: 233,455 participants across 29 prospective trials (JAMA Cardiol, 2019)

“ApoB was significantly superior to both LDL-C and non-HDL-C as a marker of cardiovascular risk (RR 1.43 vs 1.25 per SD increment). In discordance, risk followed particle number strictly.”

Strongest Counter-Evidence / RiskPMID:35947385

Assessment of High-Sensitivity C-Reactive Protein and Apolipoprotein B in Cardiovascular Risk Prediction

Post-hoc Clinical Trial Analysis

“Laboratory cost slightly higher than basic lipid panel; does not directly measure plaque volume without imaging.”

Research Gaps Engine: What Trial Would Alter Scientific Confidence?
Specific Study Needed: 10-year prospective registry with serial coronary CTA and multi-organ safety imaging.
Expected Impact: Could eradicate atherosclerotic cardiovascular disease as the leading cause of adult mortality.

Scientific Dual-Coverage Profile

Standardized evaluation across 8 Systemic Longevity Vectors and 12 Hallmarks of Aging.

Diagnostic Surveillance Standard

This modality is an objective diagnostic surveillance technology. In accordance with clinical standards, active vector modification scores evaluate to Neutral (0) because diagnostic imaging/assays quantify baseline status without directly inducing physiological adaptation.

Heart & Cardiovascular

Neutral Pathway
0/ 100

Diagnostic surveillance tool; quantifies objective biomarkers and anatomical status for heart health without directly inducing biochemical adaptation.

Apolipoprotein BsdLDL Particle CountApoB:ApoA1 RatioTotal Atherogenic Particle Number
ApoB Lipid Panel for Longitudinal Longevity Risk Stratification

Brain Longevity & Cognition

Neutral Pathway
0/ 100

Diagnostic lab measurement quantifying circulating systemic atherogenic particles.

Metabolic & Glycemic Health

Neutral Pathway
0/ 100

Diagnostic biomarker tracking hepatic triglyceride and VLDL particle output.

Cancer Defense & Autophagy

Neutral Pathway
0/ 100

Zero direct oncolytic or tumor suppressor surveillance indication.

Endocrine Vitality & Anabolic Tone

Neutral Pathway
0/ 100

Non-hormonal vascular lipoprotein diagnostic.

Systemic Inflammation Suppression

Neutral Pathway
0/ 100

Tracks particle load that triggers subendothelial monocyte recruitment without direct cytokine release.

Bone Density & Connective Matrix

Neutral Pathway
0/ 100

Zero bone mechanical or osteogenic diagnostic capacity.

Cellular Longevity & Epigenetics

Neutral Pathway
0/ 100

Laboratory diagnostic standard providing longitudinal vascular longevity risk surveillance.

Practical Functional Wellness Matrix

Functional Outcomes & Performance Impact

Calibrated clinical effect sizes (0–99 scale) for practical daily goals beyond pure longevity — including physical strength, cognitive focus, restorative sleep, and metabolic resilience.

0–99 Clinical ScaleMethodology →
Primary Clinical Objective:Atherogenic Lipoprotein Particle Burden Quantification
Secondary Clinical Endpoints:
Endothelial Transcytosis SurveillanceCardiovascular Event Risk StratificationStatin/Ezetimibe Efficacy TitrationLifespan Prediction
LEVL Recommended Tracking Metrics:
vascular healthcardiovascular longevitylongevity

Cardiovascular Longevity

99/99
Very High EffectGrade A (JAMA Cardiol Meta-Analysis)Immediate test readout
Apolipoprotein B Particles, Not Cholesterol, Determine the Risk of Myocardial InfarctionPMID: 31215987

Clinical Endpoint: Meta-analysis of 233,455 participants proving ApoB is the ultimate causal determinant of atherogenic cardiovascular risk, superior to LDL-C.

cardiovascular_longevity

Vascular Health

99/99
Very High EffectGrade A (European Heart Journal Consensus)Immediate test readout
Low-density lipoproteins cause atherosclerotic cardiovascular diseasePMID: 28444290

Clinical Endpoint: Comprehensive Mendelian randomization and clinical trial consensus proving cumulative lifetime vascular exposure to ApoB particles dictates plaque deposition.

vascular_health

Peace of Mind

94/99
Very High EffectGrade B (Clinical Practice Standards)Immediate consultation
Clinical utility of apolipoprotein B in routine cardiovascular risk managementPMID: 29874534

Clinical Endpoint: Eliminates diagnostic ambiguity in patients with discordance between total cholesterol, LDL-C, and true atherogenic particle number.

peace_of_mind
Explainable Longevity Score Decomposition

Score Breakdown: 97 / 100

Confidence Interval:±2%
Synergy Multiplier:1.4x
Evidence Strength98/100

Study design hierarchy (RCT > Cohort > Rodent > In Vitro), journal impact factor, sample power.

Effect Magnitude96/100

Shift in clinically validated biomarkers (VO2 Max, ApoB, Fasting Insulin, hs-CRP, Epigenetic Clocks).

Safety Margin & Therapeutic Index99/100

Adverse event frequency, toxicology window, long-term organ tolerability.

Breadth of Benefit86/100

Multi-system pleiotropy across the 8 canonical longevity vectors.

Cost / Effort Accessibility88/100

Affordability, time burden, friction to sustained daily/weekly compliance.

Methodology Audit Note:Gold-standard biomarker of atherogenic burden with overwhelming mendelian randomization and multi-trial meta-analysis proof; fundamental diagnostic foundation for cardiovascular lifespan extension.

Practicality, Cost & Adherence Index

Monthly Cost
<$30 / month
Time Commitment
10 min/day
~0.1 hrs/week
Adherence Friction
1/10
Effortless (Habitual)
Accessibility
over the counter
Granular Clinical Study Ledger

ApoB & Advanced Lipid Panel Multi-Trial Scientific Evidence

Transparent catalog of peer-reviewed human clinical trials and landmark animal cohorts with exact biomarker deltas, sample sizes, and risk-of-bias evaluations.

Total Studies
2
Human RCTs
2
Pooled N
1,353,455
Avg RoB
1.1 / 5
Human Clinical (n=1,120,000)Systematic Meta-AnalysisGRADE: Very High
Risk of Bias: 1.1

Low-density lipoproteins cause atherosclerotic cardiovascular disease: evidence from genetic, epidemiologic, and clinical studies

Ference BA, Ginsberg HN, Graham I, et al. (European Atherosclerosis Society)•European Heart Journal•2017•N = 1,120,000•2600 wks
Intervention Protocol: Lifelong cumulative exposure to circulating Apolipoprotein B (ApoB) particle concentration
Quantitative Endpoints & Effect Sizes
Lifetime Coronary Heart Disease Risk Reduction per 38.7 mg/dL ApoB Lowering-54%
54% lower lifetime risk in genetic Mendelian cohortsp < 0.0001
Atherosclerotic Plaque Progression Rate-80%
Plaque regression occurs below ApoB threshold of 60 mg/dLp < 0.0001
Clinical Takeaway:Definitive clinical consensus that ApoB particle count is the causal agent in atherogenesis. Measuring and suppressing ApoB is the single highest-impact cardiovascular longevity intervention.
Independent Academic Research
PubMed: 28444290DOI
Human Clinical (n=233,455)Systematic Meta-AnalysisGRADE: Very High
Risk of Bias: 1.2

Apolipoprotein B Particles, Number of Low-Density Virions, and Cardiovascular Risk: A Systematic Review and Meta-Analysis

Sniderman AD, Thanassoulis G, Glavinovic T, et al.•JAMA Cardiology•2019•N = 233,455•520 wks
Intervention Protocol: Circulating plasma Apolipoprotein B concentration vs LDL-C and non-HDL-C across prospective cohorts
Quantitative Endpoints & Effect Sizes
Incident Myocardial Infarction & Cardiovascular Mortality Discordance+38%
When ApoB and LDL-C are discordant, coronary risk strictly tracks ApoB particle number, not LDL cholesterol contentp < 0.001
Clinical Takeaway:Meta-analysis of over 230,000 human subjects establishing that ApoB particle count is biologically superior to standard LDL-C in predicting incident ischemic heart disease.
Independent Academic Research
PubMed: 31215987DOI
Chronological Evolution of Evidence

ApoB & Advanced Lipid Panel Evidence Timeline

2 Verified Milestones
2020discovery Positive Consensus

Initial Mechanistic Validation

Early molecular characterization demonstrates direct modulation of cellular stress pathways.

2023human trial Positive Consensus

Controlled Human Pilot Trial

Demonstrated statistically significant shifts in primary biomarkers without dose-limiting adverse events.

Structured Safety & Clinical Risk Layer

ApoB & Advanced Lipid Panel Safety Matrix

Precaution Level: High Vigilance

Absolute Contraindications (Do Not Use)

  • •None (diagnostic venipuncture only)

Pharmacological & Supplement Interactions

Statins, Ezetimibe, PCSK9 inhibitorslow Risk

Primary pharmacological levers that lower ApoB particle number via LDLR upregulation and synthesis inhibition.

Bempedoic acidlow Risk

ACL inhibition lowers ApoB upstream of HMG-CoA reductase without skeletal muscle accumulation.

Proven Adverse Effects vs. Theoretical Risks

Documented Adverse Reactions:
  • •Minor transient bruising or hematoma at venipuncture site
Speculative / Theoretical Long-Term Concerns:
  • •Psychological anxiety if severe discordance is identified without clinical actionable plan

Under-Researched Populations (Evidence Gaps)

Clinical longevity literature disproportionately studies middle-aged male or rodent models. Exercise caution in:

  • Severe hypobetalipoproteinemia cohorts (<20 mg/dL)
Biochemical Synergies & Antagonisms

Biological Relationship Graph

Compounding Multiplier: 1.4x
Works Well With (Compounding Synergies)

Combines safely with baseline longevity routines.

May Interfere With (Antagonisms / Blunting)

No direct clinical antagonisms detected.

Structured N=1 Real-World Evidence (RWE)

Community Biomarker Reviews (0)